Intravenous immunoglobulins for the treatment of the hyper-inflammatory response in COVID-19. Another failure of immunomodulatory therapy?

類似資料

• Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab
  著者:: Balasubramanian, S., 等
  出版事項: (2020)
• Intravenous immunoglobulin therapy in COVID-19-related encephalopathy
  著者:: Muccioli, Lorenzo, 等
  出版事項: (2020)
• The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease
  著者:: Burns, Jane C., 等
  出版事項: (2015)
• Intravenous immunoglobulin immunotherapy for coronavirus disease‐19 (COVID‐19)
  著者:: Galeotti, Caroline, 等
  出版事項: (2020)
• Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients
  著者:: Fernández-Ruiz, Mario, 等
  出版事項: (2020)